Screener
Sutro Biopharma STRO Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $73,682 | $58,130 |
| Marketable securities | 128,876 | 83,298 |
| Accounts receivable | 12,484 | 3,977 |
| Prepaid expenses and other current assets | 5,930 | 5,521 |
| Total current assets | 220,972 | 150,926 |
| Property and equipment, net | 9,363 | 10,648 |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's cash & equivalents?
- Sutro Biopharma (STRO) reported cash & equivalents of $73.68M in Q1 2026.
- How has Sutro Biopharma's cash & equivalents changed year-over-year?
- Sutro Biopharma's cash & equivalents decreased by 30.6% year-over-year, from $106.23M to $73.68M.
- What is the long-term trend for Sutro Biopharma's cash & equivalents?
- Over 5 years (2020 to 2025), Sutro Biopharma's cash & equivalents has grown at a -22.4% compound annual growth rate (CAGR), from $206.15M to $58.13M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Sutro Biopharma's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude